Pressor and renal regional hemodynamic effects of urotensin II in neonatal pigs

Journal of Endocrinology

Volumn 217, Issue 3, 2013, Pages 317-326

  Soni, Hitesh ^a   Adebiyi, Adebowale ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Mean arterial pressure; Neonates; Renal arterioles; Renal hemodynamics; Urotensin II

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 AMINOETHOXY DIPHENYLBORATE; INOSITOL 1,4,5 TRISPHOSPHATE DERIVATIVE; LOSARTAN; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN II;

ANIMAL EXPERIMENT; ARTICLE; BLOOD FLOWMETRY; BLOOD PRESSURE; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER;

MEAN ARTERIAL PRESSURE; NEONATES; RENAL ARTERIOLES; RENAL HEMODYNAMICS; UROTENSIN II;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANIMALS, NEWBORN; ARTERIAL PRESSURE; BORON COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRENES; HEMODYNAMICS; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTORS; KIDNEY; LOSARTAN; PEPTIDE FRAGMENTS; PYRROLIDINONES; RENAL CIRCULATION; SWINE; TYPE C PHOSPHOLIPASES; UROTENSINS; VASCULAR RESISTANCE;

EID: 84878809521     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0556     Document Type: Article

References (53)

1. Abdel-Razik AE, Balment RJ & Ashton N 2008a Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II. American Journal of Physiology. Renal Physiology 295 F1239-F1247. (doi:10.1152/ ajprenal.90374.2008)
2. Abdel-Razik AE, Forty EJ, Balment RJ & Ashton N 2008b Renal haemodynamic and tubular actions of urotensin II in the rat. Journal of Endocrinology 198 617-624. (doi:10.1677/JOE-08-0260)
3. Adebiyi A, Zhao G, Narayanan D, Thomas-Gatewood CM, Bannister JP & Jaggar JH 2010 Isoform-selective physical coupling of TRPC3 channels to IP3 receptors in smooth muscle cells regulates arterial contractility. Circulation Research 106 1603-1612. (doi:10.1161/CIRCRESAHA. 110.216804)
4. Adebiyi A, Thomas-Gatewood CM, Leo MD, Kidd MW, Neeb ZP & Jaggar JH 2012 An elevation in physical coupling of type 1 inositol 1,4,5- trisphosphate (IP3) receptors to transient receptor potential 3 (TRPC3) channels constricts mesenteric arteries in genetic hypertension. Hypertension 60 1213-1219. (doi:10.1161/HYPERTENSIONAHA. 112.198820)
5. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW et al. 1999 Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 282-286. (doi:10.1038/45809)
6. Ashton N 2006 Renal and vascular actions of urotensin II. Kidney International 70 624-629. (doi:10.1038/sj.ki.5001621)
7. Badzynska B, rzelec-Mojzesowicz M, Dobrowolski L & Sadowski J 2002 Differential effect of angiotensin II on blood circulation in the renal medulla and cortex of anaesthetised rats. Journal of Physiology 538 159-166. (doi:10.1113/jphysiol.2001.012921)
8. Balat A, Karakok M, Yilmaz K & Kibar Y 2007 Urotensin-II immunoreactivity in children with chronic glomerulonephritis. Renal Failure 29 573-578. (doi:10.1080/08860220701392108)
9. Berridge MJ 1993 Inositol trisphosphate and calcium signalling. Nature 361 315-325. (doi:10.1038/361315a0)
10. Bootman MD, Collins TJ, MacKenzie L, Roderick HL, Berridge MJ & Peppiatt CM 2002 2-Aminoethoxydiphenyl borate (2-APB) is a reliable blocker of store-operated Ca2C entry but an inconsistent inhibitor of InsP3-induced Ca2C release. FASEB Journal 16 1145-1150. (doi:10.1096/ fj.02-0037rev)
11. Bottrill FE, Douglas SA, Hiley CR & White R 2000 Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. British Journal of Pharmacology 130 1865-1870. (doi:10.1038/sj.bjp.0703513) Boucard AA, Sauve SS, Guillemette G, Escher E & Leduc R 2003 Photolabelling the rat urotensin II/GPR14 receptor identifies a ligandbinding site in the fourth transmembrane domain. Biochemical Journal 370 829-838. (doi:10.1042/BJ20021566)
12. Conlon JM, Arnold-Reed D & Balment RJ 1990 Post-translational processing of prepro-urotensin II. FEBS Letters 266 37-40. (doi:10.1016/ 0014-5793(90)81500-N)
13. Coulouarn Y, Lihrmann I, Jegou S, Anouar Y, Tostivint H, Beauvillain JC, Conlon JM, Bern HA & Vaudry H 1998 Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. PNAS 95 15803-15808. (doi:10.1073/pnas.95.26.15803)
14. Dobrydneva Y & Blackmore P 2001 2-Aminoethoxydiphenyl borate directly inhibits store-operated calcium entry channels in human platelets. Molecular Pharmacology 60 541-552.
15. Dominguez-Rodriguez A, Diaz I, Rodriguez-Moyano M, Calderon-Sanchez E, Rosado JA, Ordonez A & Smani T 2012 Urotensin-II signaling mechanism in rat coronary artery: role of STIM1 and Orai1-dependent store operated calcium influx in vasoconstriction. Arteriosclerosis, Thrombosis, and Vascular Biology 32 1325-1332. (doi:10.1161/ATVBAHA.111.243014)
16. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH & Willette RN 2000 Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. British Journal of Pharmacology 131 1262-1274. (doi:10.1038/sj.bjp.0703690)
17. Douglas SA, Dhanak D & Johns DG 2004 From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends in Pharmacological Sciences 25 76-85. (doi:10.1016/j.tips.2003.12.005)
18. Fontes-Sousa AP, Pires AL, Monteiro-Cardoso VF & Leite-Moreira AF 2009 Urotensin II-induced increase in myocardial distensibility is modulated by angiotensin II and endothelin-1. Physiological Research 58 653-660. Forty EJ & Ashton N 2012 Ontogeny of the renal urotensin II system in the rat. Experimental Physiology 97 785-795.
19. Gibson A, Wallace P & Bern HA 1986 Cardiovascular effects of urotensin II in anesthetized and pithed rats. General and Comparative Endocrinology 64 435-439. (doi:10.1016/0016-6480(86)90080-8)
20. Giuliani L, Lenzini L, Antonello M, Aldighieri E, Belloni AS, Fassina A, Gomez-Sanchez C & Rossi GP 2009 Expression and functional role of urotensin-II and its receptor in the adrenal cortex and medulla: novel insights for the pathophysiology of primary aldosteronism. Journal of Clinical Endocrinology and Metabolism 94 684-690. (doi:10.1210/ jc.2008-1131)
21. Gong H, Wang YX, Zhu YZ, Wang WW, Wang MJ, Yao T & Zhu YC 2004 Cellular distribution of GPR14 and the positive inotropic role of urotensin II in the myocardium in adult rat. Journal of Applied Physiology 97 2228-2235. (doi:10.1152/japplphysiol.00540.2004)
22. Heyman SN, Kaminski N & Brezis M 1995 Dopamine increases renal medullary blood flow without improving regional hypoxia. Experimental Nephrology 3 331-337.
23. Hook JB & Bailie MD 1979 Perinatal renal pharmacology. Annual Review of Pharmacology and Toxicology 19 491-509. (doi:10.1146/annurev.pa.19. 040179.002423)
24. Igbe I, Omogbai EK & Oyekan AO 2012 Differential effects of angiotensin II on intra-renal hemodynamics in rats; contribution of prostanoids, NO and KC channels. Pharmacology & Pharmacy 3 388-396. (doi:10.4236/ pp.2012.34052)
25. Ishihata A, Ogaki T, Aita T & Katano Y 2005 Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. European Journal of Pharmacology 523 119-126. (doi:10.1016/ j.ejphar.2005.09.018)
26. Itoh H, Itoh Y, Rivier J & Lederis K 1987 Contraction of major artery segments of rat by fish neuropeptide urotensin II. American Journal of Physiology 252 R361-R366.
27. Langham RG, Kelly DJ, Gow RM, Zhang Y, Dowling JK, Thomson NM &Gilbert RE 2004 Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. American Journal of Kidney Diseases 44 826-831.
28. Lin Y, Tsuchihashi T, Matsumura K, Abe I & Iida M 2003 Central cardiovascular action of urotensin II in conscious rats. Journal of Hypertension 21 159-165. (doi:10.1097/00004872-200301000-00026)
29. Liu Q, Pong SS, Zeng Z, Zhang Q, Howard AD, Williams DL Jr, Davidoff M, Wang R, Austin CP, McDonald TP et al. 1999 Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochemical and Biophysical Research Communications 266 174-178. (doi:10.1006/bbrc.1999.1796)
30. Lu Y, Zou CJ, Huang DW & Tang CS 2002 Cardiovascular effects of urotensin II in different brain areas. Peptides 23 1631-1635. (doi:10.1016/S0196-9781(02)00104-3)
31. MacLeanMR, AlexanderD, Stirrat A, GallagherM, Douglas SA, Ohlstein EH, Morecroft I&PollandK2000 Contractile responses tohuman urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. British Journal of Pharmacology 130 201-204. (doi:10.1038/sj.bjp.0703314)
32. Maguire JJ, Kuc RE & Davenport AP 2000 Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison ofvasoconstrictor responses with endothelin-1. British Journal of Pharmacology 131 441-446. (doi:10.1038/sj.bjp.0703601)
33. Matsushita M, Shichiri M, Imai T, Iwashina M, Tanaka H, Takasu N & Hirata Y 2001 Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. Journal of Hypertension 19 2185-2190. (doi:10.1097/00004872-200112000-00011)
34. Mattson DL 2003 Importance of the renal medullary circulation in the control of sodium excretion and blood pressure. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 284 R13-R27.
35. Mattson DL & Cowley AW Jr 1993 Kinin actions on renal papillary blood flow and sodium excretion. Hypertension 21 961-965. (doi:10.1161/ 01.HYP.21.6.961)
36. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM & Mitchell KD 1996 Paracrine regulation of the renal microcirculation. Physiological Reviews 76 425-536.
37. Nobes MS, Harris PJ, Yamada H & Mendelsohn FA 1991 Effects of angiotensin on renal cortical and papillary blood flows measured by laser-Doppler flowmetry. American Journal of Physiology 261 F998-F1006
38. Ovcharenko E, Abassi Z, Rubinstein I, Kaballa A, Hoffman A & Winaver J 2006 Renal effects of human urotensin-II in rats with experimental congestive heart failure. Nephrology, Dialysis, Transplantation 21 1205-1211. (doi:10.1093/ndt/gfk049)
39. Pallone TL, Robertson CR & Jamison RL 1990 Renal medullary microcirculation. Physiological Reviews 70 885-920. Ponnuchamy B & Khalil RA 2009 Cellular mediators of renal vascular dysfunction in hypertension. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 296 R1001-R1018. (doi:10.1152/ ajpregu.90960.2008)
40. Ponnuchamy B & Khalil RA 2009 Cellular mediators of renal vascular dysfunction in hypertension. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
41. Ross B,McKendy K&Giaid A 2010 Role of urotensin II in health and disease. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 298 R1156-R1172. (doi:10.1152/ajpregu.00706.2009)
42. Saetrum OO, Nothacker H, Ehlert FJ & Krause DN 2000 Human urotensin II mediates vasoconstriction via an increase in inositol phosphates. European Journal of Pharmacology 406 265-271. (doi:10.1016/ S0014-2999(00)00672-5)
43. Sanders KM 2001 Invited review: mechanisms of calcium handling in smooth muscles. Journal of Applied Physiology 91 1438-1449. Shi Y, Cao YX, Lu N, Yao T & Zhu YC 2008 Hemodynamic-independent anti-natriuretic effect of urotensin II in spontaneously hypertensive rats. Peptides 29 783-794. (doi:10.1016/j.peptides.2008.02.015)
44. Simpson CM, Smolich JJ, Shekerdemian LS & Penny DJ 2010 Urotensin-II contributes to pulmonary vasoconstriction in a perinatal model of persistent pulmonary hypertension of the newborn secondary to meconium aspiration syndrome. Pediatric Research 67 150-157. (doi:10.1203/PDR.0b013e3181c345ea)
45. Song W, Abdel-Razik AE, Lu W, Ao Z, Johns DG, Douglas SA, Balment RJ & Ashton N 2006 Urotensin II and renal function in the rat. Kidney International 69 1360-1368.
46. Stirrat A, Gallagher M, Douglas SA, Ohlstein EH, Berry C, Kirk A, Richardson M & MacLean MR 2001 Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. American Journal of Physiology. Heart and Circulatory Physiology 280 H925-H928.
47. Takezawa K, Cowley AW Jr, Skelton M & Roman RJ 1987 Atriopeptin III alters renal medullary hemodynamics and the pressure-diuresis response in rats. American Journal of Physiology 252 F992-F1002.
48. Toth-Heyn P, Drukker A & Guignard JP 2000 The stressed neonatal kidney: from pathophysiology to clinical management of neonatal vasomotor nephropathy. Pediatric Nephrology 14 227-239. (doi:10.1007/ s004670050048)
49. Tsoukas P, Kane E & Giaid A 2011 Potential clinical implications of the urotensin II receptor antagonists. Frontiers in Pharmacology 2 38. (doi:10.3389/fphar.2011.00038)
50. Wang YX, Ding YJ, Zhu YZ, Shi Y, Yao T & Zhu YC 2007 Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. American Journal of Physiology. Heart and Circulatory Physiology 292 H348-H359. (doi:10.1152/ajpheart. 00512.2006)
51. 2+ release. Circulation Research 102 1118-1126. (doi:10.1161/CIRCRESAHA. 108.173948)
52. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, de Garavilla L, Li PL & Zou AP 2003 Urotensin II is a nitric oxidedependent vasodilator and natriuretic peptide in the rat kidney. American Journal of Physiology. Renal Physiology 285 F792-F798.
53. Zoccali C & Mallamaci F 2008 Urotensin II: a cardiovascular and renal update. Current Opinion in Nephrology and Hypertension 17 199-204. (doi:10.1097/MNH.0b013e3282f49566)